Polymorphisms in FKBP51 are associated with stress-related psychiatric disorders and influence the severity of pain symptoms experienced after trauma. We report that FKBP51 (FK506 binding protein 51) is crucial for the full development and maintenance of long-term pain states. Indeed, FKBP51 knockout mice, as well as mice in which silencing of FKBP51 is restricted to the spinal cord, showed reduced hypersensitivity in several persistent pain models in rodents. FKBP51 deletion did not compromise the detection of acute painful stimuli, a critical protective mechanism. Moreover, the intrathecal administration of the specific FKBP51 inhibitor SAFit2 reduced the severity of an established pain state, confirming the crucial role of spinal FKBP51 in nociceptive processing. Finally, glucocorticoid signaling, which is known to modulate persistent pain states in rodents, was impaired in FKBP51 knockout mice. This finding suggested that FKBP51 regulates chronic pain by modulation of glucocorticoid signaling. Thus, FKBP51 is a central mediator of chronic pain, likely in humans as well as rodents, and is a new pharmacologically tractable target for the treatment of long-term pain states.
INTRODUCTION
Genetic variants in FKBP51 are associated with major depression and posttraumatic stress disorder (PTSD) in humans (1, 2) , and mice lacking the gene FKBP51 show improved coping behavior under stress, without alterations to their attention or motor functions (3) (4) (5) . Variations in the gene FKBP51 influence the severity of musculoskeletal pain symptoms experienced during the weeks after motor vehicle collision or after sexual assault (6, 7) . Furthermore, as we have previously reported in a microarray study, FKBP51 (FK506 binding protein 51) is up-regulated in the rat superficial dorsal horn after derepression by the methyl CpG binding protein 2 (MeCP2) within 2 hours of ankle joint inflammation (8) (9) (10) . We therefore hypothesized that FKBP51 contributes to injuryinduced pain hypersensitivity. We have tested this hypothesis here by using knockout (KO) mice, small interfering RNA (siRNA) technology, and the recently developed FKBP51 inhibitor SAFit2 (11) .
FKBP51 is up-regulated after activation of the glucocorticoid receptor (GR) by steroids (12) and, in a negative feedback loop, modulates the stress response by antagonizing GR and regulating its sensitivity (13) . Moreover, it has been proposed that GR signaling regulates the hypersensitivity that develops in long-term pain states (14) (15) (16) . Using behavioral, pharmacological, and molecular tools, we test here the role of spinal FKBP51 on long-term pain states and their regulation by glucocorticoid signaling.
RESULTS

FKBP51 increases in the spinal cord after noxious stimulation
Using immunohistochemistry with tyramide amplification, we found that FKBP51 was expressed exclusively in neurons of the superficial dorsal horn of both naïve and mice injected with complete Freund's adjuvant (CFA) in the ankle joint ( Fig. 1 ). Using quantitative reverse transcription polymerase chain reaction (RT-qPCR), we then confirmed that FKBP51 mRNA was increased significantly in both rats and mice after ankle joint inflammation induced by injection of CFA in the ankle joint: FKBP51 mRNA was up-regulated in the dorsal horn in the rat at 2 and 6 hours after CFA and in the mouse at 24 hours and 3 days after CFA ( Fig. 2A) . As we have reported, this increase in FKBP51 mRNA correlates with an increase in FKBP51 protein in the rat (10) . No changes in FKBP51 mRNA were observed in L4 and L5 dorsal root ganglia (DRGs) or in the cervical cord, Fig. 1 . FKBP51 is expressed exclusively in neurons in mouse dorsal horn. (A) Typical images of FKBP51 immunoreactivity in the superficial dorsal horn of wild-type (WT) and KO animals. Dotted line indicates the boundary of the superficial dorsal horn. Scale bars, 100 mm. (B) FKBP51 immunoreactivity in the ipsilateral dorsal horn 3 days after CFA injection in the ankle joint. FKBP51 was never seen in microglia. Green, FKBP51; red, Iba1 (a marker of microglia); blue, NeuN (a marker of neurons). Scale bar, 20 mm. (C) FKBP51 immunoreactivity in the ipsilateral dorsal horn 3 days after CFA injection in the ankle joint. FKBP51 expression was never seen in astrocytes. Green, FKBP51; red, GFAP (a marker of astrocytes); blue, NeuN (a marker of neurons). Scale bar, 20 mm.
indicating that there was a localized spinal response to the CFA injection.
In people carrying specific variants of FKBP51, childhood trauma can induce a decrease in DNA methylation in the promoter of FKBP51. This demethylation enhances stress-dependent expression of FKBP51 and is associated with a higher risk of developing PTSD in adult life (2) . We therefore examined whether noxious stimulation could also induce changes in FKBP51 DNA methylation. For this, we performed bisulphite pyrosequencing on rat superficial dorsal horn tissue after injection of CFA into the ankle joint and observed a fast (2 hours after CFA) and long-lasting (7 days after CFA) ipsilateral decrease in methylation at specific CpG sites previously identified in the promoter sequence of FKBP51 (17) (Fig. 2 , B and C). This suggested that changes in DNA methylation might contribute to the rapid increase in spinal FKBP51 levels after CFA and that FKBP51 may regulate both the development and maintenance of long-term pain states. To test this hypothesis, we next used FKBP51 KO mice and their wild-type littermates.
Global deletion of FKBP51 has no effect on naïve thresholds and the short-term inflammatory response We found no difference in the cutaneous mechanical sensory threshold (Fig. 3A) or thermal heat (Fig. 3B ) and cold ( Fig. 3C ) thresholds between KO and wild-type animals, suggesting that acute nociception was not impaired by FKBP51 deletion. This conclusion was supported by the normal expression of primary afferent markers IB4 and CGRP in the superficial dorsal horn in these mice ( Fig. 3D and fig. S1 ). Moreover, there was no difference between the two genotypes in the nociceptive sensitivity that follows the hindpaw injection of shortterm inflammatory agents such as formalin (Fig. 2E ) or interleukin-6 (IL6) (Fig. 2F ). These data suggested that deletion of FKBP51 does not impair acute pain responses.
Global deletion of FKBP51 prevents the full development of long-term pain states We next tested the effect of FKBP51 KO on long-term pain states. Although both KO and wild-type mice showed a significant reduction in mechanical threshold after CFA injection in the ankle joint, KO mice were less sensitive than wild-type mice (Fig. 4A) . However, there was no difference in CFA-induced spinal phosphorylated extracellular signal-regulated kinase (pERK) (Fig. 4B and fig. S2A ) and cFos ( Fig.  4B and fig. S2B ). Similarly, hindpaw injection of CFA, which induces long-term inflammation, caused significantly less mechanical hypersensitivity in KO than in wild-type mice (Fig. 4C) , despite causing the same degree of edema in the hindpaw (Fig. 4D) . Finally, to test whether the modulatory role of FKBP51 on persistent pain states extended beyond long-term inflammation, we also investigated a model of neuropathic pain. KO mice with spared nerve injury (SNI) (18) showed less mechanical hypersensitivity than wild-type mice, starting at 5 days after surgery (Fig. 4E) . They also performed better on the rotarod test (Fig. 4F) , likely a result of reduced mechanical hyperalgesia, as well as increased ability to cope with stress (3, 4) . However, glial activation, which contributes to the hypersensitivity seen in neuropathic pain states (19) , was not different in KO mice 14 days after SNI surgery than that in wild-type mice ( fig.  S3, A and B) . Together, these results showed that FKBP51 KO mice display reduced mechanical hypersensitivity in long-term pain states, suggesting that FKBP51 is required for full development of persistent pain states. Because our previous findings (10) suggested a role for spinal FKBP51 in pain processing, we next used siRNA to determine whether FKBP51 specifically expressed in the spinal cord contributed to nociceptive signaling.
Spinal FKBP51 drives long-term pain states
We specifically deleted FKBP51 in the spinal cords of wild-type mice using intrathecal injections of siRNA. Injections of siRNA reduced FKBP51 expression in the spinal cord by 24% but had no effect on FKBP51 expression in the DRGs ( fig. S4A ). This decrease in FKBP51 expression is similar to that reported by others when intrathecally injecting siRNA, a treatment known to have a significant effect on behavior (20) . This deletion is likely to have occurred in neurons exclusively because in the superficial dorsal horn, we found that only neurons expressed FKBP51 (by using immunohistochemistry with tyramide amplification). Although siRNA injections did not affect mechanical threshold and motor performance in naïve animals ( fig.  S4 , B and C, respectively), siRNA injections starting 48 hours before the CFA injection significantly reduced the mechanical hypersensitivity induced by CFA-triggered ankle joint inflammation when compared to scramble siRNA injections (Fig. 5A ). Because it mimics the clinical situation, siRNA silencing of FKBP51 starting 3 days after injury, when hypersensitivity was maximal, significantly attenuated the pain state (Fig. 5B) .
We then used the highly specific FKBP51 inhibitor SAFit2 (11) to block FKBP51 activity. Like anti-FKBP51 siRNA treatment, SAFit2 administered intrathecally improved the mechanical hypersensitivity induced by ankle joint inflammation when injected 3 days after the CFA treatment (Fig. 5C ), suggesting that FKBP51 may be a promising therapeutic target for the treatment of chronic pain.
Thus, spinal FKBP51 is not only sufficient for the full development of chronic pain but also critical to the maintenance of this pain. We next explored the mechanism by which FKBP51 regulates nociceptive processing.
FKBP51 regulates injury-induced hypersensitivity by modulating glucocorticoid signaling FKBP51 is an antagonist of GR (13), and GR signaling regulates the hypersensitivity that develops after nerve injury (14, 15) . We therefore hypothesized that FKBP51 regulates the hypersensitivity that develops in long-term pain states by modulating glucocorticoid signaling. We studied the coexpression of FKBP51 and GR in wild-type superficial dorsal horn with immunohistochemistry. We found that colocalization of FKBP51 and GR was equivalent in tissue from both sham-treated mice and mice injected with CFA in the ankle joint, with an average of 84 ± 1% of FKBP51-positive neurons expressing GR (85.5 ± 4%, CFA ipsilateral; 83.7 ± 1%, CFA contralateral; and 82.1 ± 1%, sham) and 81 ± 1% of GR-positive neurons expressing FKBP51 (78.7 ± 7%, CFA ipsilateral; 82.7 ± 2%, CFA contralateral; and 81.2 ± 4%, sham) (n = 3 mice per group; three sections counted per mouse and 30 to 70 neurons counted per half section; Fig. 6A ).
GR has two main isoforms in both humans and rodents, GRa and GRb, each associated with a distinct response to glucocorticoid hormones (21) . In the spinal cord, we found a small difference in total GR mRNA expression between FKBP51 KO and wild-type mice (Fig. 6B) . Nevertheless, CFA injection to the ankle joint did not induce any significant changes in GR mRNA levels in either genotype, and we found no difference in GR protein levels between KO and wild-type mice, in both naïve and CFA-injected animals ( fig. S5 ). There was also no difference in GRa mRNA levels between KO and wild-type, in both naïve and CFA-injected animals; however, both wild-type and KO mice showed increased GRb levels on the side ipsilateral to the CFA injection compared to the contralateral side, and levels of GRb were significantly lower in KO animals than in wild-type animals (Fig. 6B ). Increased GRb levels have been associated with glucocorticoid resistance in inflammatory disorders (22) . Therefore, our results suggest that in inflammatory pain states, KO mice are more sensitive to glucocorticoids than are wild-type mice. Supporting this interpretation, Signal intensity was normalized to WT expression levels (n = 3 per group). (E and F) In WT and KO mice (E), nociceptive behavior after intraplantar injection of formalin (n = 7 per group) and (F) mechanical hypersensitivity after intraplantar injection of IL6 (n = 6 to 7 per group). Data show means ± SEM. B1, B2, and B3: baseline data taken on separate days.
KO mice had lower corticosterone levels than wild-type mice, both in naïve and in persistent pain states (Fig. 6C) , indicating a stronger suppression of corticosterone secretion in FKBP51-deficient mice, as reported previously (3) .
Next, to test whether FKBP51 drives chronic pain by modifying GR signaling in the spinal cord, we used the GR antagonist mifepristone (RU38486). First, we intrathecally injected mifepristone in naïve animals. Both naïve wild-type and naïve KO mice showed increased mechanical hypersensitivity after mifepristone administration (Fig. 6D ), indicating that GR was antinociceptive under basal conditions, regardless of FKBP51 expression. However, when mifepristone was administered 3 days after CFA injection in the ankle joint, the GR antagonist eliminated the CFA-induced hypersensitivity in wild-type animals ( Fig. 6E and fig. S6A for full time course of behavior), as seen in neuropathic pain models (15, 16) , but aggravated CFA-induced mechanical hypersensitivity in KO mice (Fig. 6F and fig. S6B for full time course of behavior). Mifepristone also increased the CFA-induced hypersensitivity in mice with reduced levels of FKBP51 only in the : two-way ANOVA, factor GENOTYPE day 1 (D1) to D7: F 1,13 = 30.9; P < 0.0001. KO versus WT: D1, P < 0.001; D2, P < 0.001; D3, P < 0.001; D4, P < 0.001; D5, P = 0.012; D6, P = 0.002; D7, P = 0.01. Although the sensitivity induced by CFA was reduced in KO compared to WT mice, it was nonetheless significantly different from baseline values (one-way ANOVA, factor TIME B3 to D4: F 5,35 = 3.7; P = 0.008). (B) Number of pERKand cFos-positive cells in the superficial dorsal horn after CFA injection in the ankle joint, at 10 min and 2 hours after injection, respectively. Cells were counted on 40-mm sections stained by immunohistochemistry for pERK and cFos. (C) Mechanical sensitivity in KO and WT mice after intraplantar injection of CFA (n = 8 per group, two-way ANOVA, factor GENOTYPE D2 to D7: F 1,14 = 20.3, P < 0.0001; KO versus WT: D2, P = 0.024; D4, P = 0.001; D5, P = 0.022; D6, P = 0.010; D7, P < 0.001). Although the sensitivity induced by CFA was reduced in KO compared to WT mice, it was nonetheless significantly different from baseline values (one-way ANOVA, factor TIME B3 to D7: F 8,56 = 5.23, P < 0.0001). (D) Paw edema after intraplantar CFA-induced inflammation in KO, WT, and naïve mice (n = 8 per group, ANOVA TREAT-MENT F 1,21 = 70.8; P < 0.0001; D5, D7: Naïve versus WT: P < 0.001; D5, D7: Naïve versus KO: P < 0.001). i.pl., intraplantar. (E) Mechanical sensitivity in KO and WT mice after SNI (twoway ANOVA, factor GENOTYPE D5 to D14: F 1,13 = 31.6; P < 0.0001; KO versus WT: D5, P = 0.001; D6, P = 0.01; D7, P < 0.001; D8, P < 0.001; D10, P = 0.005; D14, P < 0.001, n = 7 to 8 per group). Although the sensitivity induced by CFA was reduced in KO compared to WT mice, it was nonetheless significantly different from baseline values (one-way ANOVA, factor TIME B3 to D1: F 1,6 = 8.1; P = 0.029). (F) Time on the rotarod apparatus after SNI surgery in KO and WT mice (n = 8 to 9 per group; Student's t test; D7 KO versus WT: P = 0.030; D10 KO versus WT: P = 0.020). Animals were not tested at baseline to minimize the number of tests on the rotarod. Data show means ± SEM. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001, WT versus KO in (A), (C), (E), and (F), and KO or WT CFA versus naïve in (D). Injection or surgery time is indicated by arrows.
spinal cord (Fig. 6G and fig. S6C for full time course of behavior). This result suggested that after CFA injection, spinal cord GR signaling had switched to a pronociceptive function in wild-type animals, but that the deletion of spinal cord FKBP51 had prevented this switch and restricted GR to an antinociceptive function. Finally, IL6 is a cytokine up-regulated with neuroinflammation (23, 24) , and GR can directly induce or inhibit the transcription of IL6 by complex binding to the IL6 promoter regulatory elements (25) . We measured IL6 levels in the spinal cord of wild-type and KO mice and found that IL6 was up-regulated in the ipsilateral superficial dorsal horn in wild-type mice after CFA injection (Fig. 6H) , supporting the idea that GR could be promoting proinflammatory cytokine expression in wild-type animals after CFA treatment. However, IL6 levels were significantly lower in the spinal cord of the KO mice on the side ipsilateral to the CFA injection when compared both to wild-type animals and to the KO contralateral side, suggesting that GR could be suppressing IL6 transcription on the ipsilateral side in KO mice after CFA injection (Fig. 6H) .
Together, our data indicate that spinal FKBP51 regulates the full development and maintenance of chronic pain by modulating glucocorticoid signaling. We propose that inhibition of FKBP51 function by deletion or antagonism allows spinal cord GR signaling to perform an antinociceptive function in long-term pain states. As a result, CFAinduced hypersensitivity never develops to its full extent in FKBP51 KO animals and resolves after deletion or inhibition of spinal cord FKBP51 in wild-type mice.
DISCUSSION
This study identifies the stress modulator FKBP51 as a regulator of injury-induced hypersensitivity. Our experiments show that in mice, deletion of FKBP51 did not compromise the detection of acute noxious stimuli but did attenuate the full development and maintenance of mechanical hypersensitivity in our animal models of chronic pain states. This was true whether FKBP51 was deleted before the pain-causing Threshold of mechanical sensitivity (log(g) RT-qPCR analysis of GR expression in the dorsal horn 3 days after CFA injection in the ankle joint; data normalized to WT sham. For GR data: two-way ANOVA, factor GENOTYPE F 1,66 = 9.84, P = 0.003. For GRb data: two-way ANOVA, factor GENOTYPE F 1,66 = 12.94; P = 0.001; TREATMENT F 2,66 = 4.07; P = 0.0022. Post hoc analysis: univariate analysis, KO ipsi versus WT ipsi: F 1,21 = 7.72, P = 0.011; paired Student's t test: WT ipsi versus WT contra, P = 0.001; KO ipsi versus KO contra, P = 0.029 (n = 11 to 12 per group). *P < 0.05, **P < 0.01, ***P < 0.001. (C) Concentration of plasma corticosterone in KO and WT mice before and 1 and 7 days after CFA injection in the ankle joint (n = 4 per group). CFA-injected animals were not sampled at baseline to minimize the number of blood withdrawals. Statistics show the results of a nested ANOVA. Factor GENOTYPE Naïve injury or silenced after the long-term pain state had been established. Moreover, FKBP51 regulation of pain states could be dissociated from its regulation of mood (presumably mediated through brain effects) because deletion of FKBP51 or inhibition with the state-of-the-art inhibitor SAFit2 (11) restricted to the spinal cord improved CFA-induced hypersensitivity. As a result, we propose that FKBP51 is a potential therapeutic target for the control of chronic pain with promising clinical applications. Chronic pain is an area of immense unmet medical need that requires new analgesic drugs. FKBP51 regulates GR signaling, and GR mediates the action of steroid hormones required for physiological homeostasis. Before hormone binding, GR is part of a large protein complex localized to the cytoplasm where it is bound to heat shock protein 90 (Hsp90), which itself recruits to its COOH terminus a co-chaperone such as FKBP51 or FKBP52. Although FKBP51 likely does not directly bind GR, its presence in the protein complex induces a conformational change of the ligand-binding pocket that reduces GR hormone binding affinity (26, 27) . FKBP51 also prevents the nuclear translocation of the GR complex that occurs when Hsp90 binds FKBP52 (28) . After steroid hormone binding to GR, GR translocates to the nucleus, where it serves as a regulator of differential gene expression. Among other targets, GR can up-regulate FKBP51, thereby providing an inhibitory feedback mechanism (29, 30) . However, other factors contribute to the upregulation of FKBP51 in the spinal cord, such as neuronal activityinduced relief of MeCP2 repression [observed both in rats (10) and mice (31, 32) ] and the decrease in FKBP51 DNA methylation reported here and also seen in mice after increased cortisol concentrations (17, 33) .
Intact GR signaling is critical for the full development of pain states. Indeed, both adrenalectomy and GR knockdown in the spinal cord by intrathecal administration of siRNA prevent the full development of mechanical hypersensitivity (15) . Moreover, the GR agonist dexamethasone can unmask the hypersensitive state in injured adrenalectomized animals (15) . Here, we show that deletion of FKBP51 modulates GR signaling. Indeed, KO mice had lower blood glucocorticoid concentrations than did wild-type animals, as well as lower levels of GRb, the GR isoform up-regulated with glucocorticoid resistance (22) , suggesting that FKBP51 KO mice are more sensitive to glucocorticoids than are wild-type mice. We propose that the upregulation of FKBP51 after CFA treatment, together with the subsequent binding of FKBP51 to the GR complex, could be a trigger that switches GR from an anti-to a pronociceptive role. Our data obtained with the GR antagonist mifepristone indicate that GR signaling was antinociceptive in naïve wild-type mice but became pronociceptive after CFA injection and pain state development (Fig. 6, D and E) . We were confident that mifepristone acted as an inhibitor of GR because others had reported that injury-induced hypersensitivity could be reduced by both mifepristone and another more specific GR antagonist, dexamethasone 21-mesylate, in mice (16) . Our result indicating a change in GR activity is consistent with recent data suggesting that GR can switch from an anti-inflammatory state under naïve conditions to a proinflammatory state after exposure to stressors (34) . In contrast, after FKBP51 deletion, GR signaling induced a constant antinociceptive state (Fig. 5, D, F, and G) . The rapid effects of the GR antagonist mifepristone reported here are most likely to reflect nongenomic activity of GR, such as modulation of the MAPK (mitogenactivated protein kinase) and PI3K (phosphatidylinositol 3-kinase) signal transduction pathways. However, GR can act both genomically (up-regulation and inhibition of gene expression) and non-genomically after activation by glucocorticoids and/or posttranslational modification such as phosphorylation (35) . We hypothesized that for optimal efficiency, non-genomic and genomic actions of GR worked in concert toward pro-or antinociceptive signaling at a given time point. That this is the case is supported by our finding that the increase in expression of the proinflammatory cytokine IL6 (24) , observed in the ipsilateral dorsal horn of wild-type animals after CFA treatment, did not occur in KO mice. GR can bind to the IL6 promoter sequence in rodent neurons, and the GR agonist dexamethasone can induce IL6 transcription in these neurons (36) . However, the GR both promotes and inhibits the expression of IL6 (25, 34) . Gene regulation by GR is highly complex and depends on a number of factors including the tissue, the concentration of circulating glucocorticoids, and GR posttranslational modifications.
We also report here that levels of DNA methylation within the FKBP51 DNA promoter sequence in the rat spinal cord are significantly lower 7 days after CFA injection. However, we have previously shown that there were no significant changes in FKBP51 mRNA expression at this time point (9) . Thus, changes in DNA methylation may not be sufficient to change FKBP51 expression in the spinal cord but need to be combined with other events, such as relief of MeCP2 repression, as we had previously reported (10) . Others have shown that stress in early life can induce long-term changes in DNA methylation in the FKBP51 sequence. These modifications lead to a much greater induction of FKBP51 when further stress is encountered later in life (2) . Together with our report of injury-induced, long-lasting changes in DNA methylation in the FKBP51 promoter, this offers the interesting perspective that FKBP51 might contribute to the excessive hypersensitivity that develops after repetitive injuries, both in rodents and in humans (37) (38) (39) .
In conclusion, this study identifies the stress regulator FKBP51 as a key modulator of long-term pain states. Our finding that the deletion or inhibition of spinal cord FKBP51 does not compromise acute pain detection but reduces hypersensitivity in mice with established inflammatory pain points to FKBP51 as a possible new target for the treatment of long-term pain states. FKBP51 inhibition is known to successfully treat mood disorders, but the development of FKBP51 antagonists has been challenging (40) . New and highly specific inhibitors for FKBP51 developed very recently, such as SAFit2 (11), can reduce signs of depression in mice in vivo (11) and, as we have shown here, inhibit established injury-associated mechanical hypersensitivity in mice. The lack of FKBP51 does not seem to induce any deleterious side effects (5); therefore, FKBP51 may be a suitable target for the long-term treatment that would be required for chronic pain.
MATERIAL AND METHODS
Study design
This study represents a series of experiments using multiple molecular and behavioral techniques in rodents. In pharmacological studies, mice were randomly assigned to experimental groups. The experimenter was always blind to genotype and treatment. Although the effect size of genotype and drug effects were not predictable, sample sizes in this study are consistent with norm in the field (41) .
Animals
Subjects in all experiments, except DNA methylation studies, were adult male mice (6 to 12 weeks old). Wild-type mice in all siRNA experiments were C57Bl/6J from Harlan Laboratories. In the remaining experiments, mice were FKBP51 KO and their wild-type littermates obtained from FKBP51 heterozygotes from C. A. Dickey's group (University of South Florida, USA). These mice were from mixed genetic backgrounds, C57Bl/6J and Swiss Webster. In the DNA methylation studies, adult rats weighing 200 to 250 g and obtained from University College London animal house were used. All animals were kept in their home cages in a temperature-controlled (20°± 1°C) environment, with a light-dark cycle of 12 hours (lights on at 7:30 a.m.). Food and water were provided ad libitum. All efforts were made to minimize animal suffering and to reduce the number of animal used (UK Animal Act, 1986).
Genotyping
For genotyping, DNA was extracted from a small portion of ear tissue, and the following primers were used for the PCR: forward wild-type and 51KO primer, AAAGGACAATGACTACTGATGAGG; reverse wild-type primer, AAGGAGGGGTTCTTTTGAGG; reverse 51KO primer, GTTGCACCACAGATGAAACG. Samples from wild-type animals showed a single PCR product of 363 base pairs (bp); samples from KO animals showed a single PCR product of 510 bp; and samples from HET animals would present both bands.
Pain models
Inflammatory models (sham treatment consisted of anesthetizing the animals). CFA induced ankle joint inflammation. Inflammation was induced by injection of CFA (Sigma) at the volume of 5 ml (mice) or 10 ml (rats), in the left ankle joint, under isoflurane anesthesia as described (10) .
Hindpaw inflammation. Formalin (20 ml, 5%), IL6 (20 ml), and CFA (20 ml) were subcutaneously injected with a microsyringe with a 27-gauge needle into the plantar surface of the left hindpaw of mice. Mice were maintained under isoflurane anesthesia during the injection except for formalin injections.
Neuropathic model: Spared nerve injury. The SNI was performed as described (18) .
Behavioral testing
The experimenter was always blind to genotype and treatment.
Von Frey hairs. Animals were placed in Plexiglas chambers, located on an elevated wire grid, and allowed to habituate for at least 1 hour. After this time, the plantar surface of the paw was stimulated with a series of ascending force von Frey monofilaments. The threshold was determined by using the up-down method as described by Chaplan and colleagues (42) . The data were expressed as log of the mean of the 50% pain threshold ± SEM.
Hargreaves test. The latency of foot withdrawal to noxious heat stimuli was measured as described (43) .
Formalin behavior. Mice were allowed to habituate to a Plexiglas chamber for at least 30 min. Behavioral testing was initiated immediately after formalin injection and lasted 60 min. The incidences of licking and biting were counted at intervals of 5 min.
Rotarod test. Motor performance was evaluated by an accelerating rotarod apparatus with a 3-cm-diameter rod starting at an initial rotation of 4 rpm and slowly accelerating to 40 rpm over 100 s. Mice were expected to walk at the speed of rod rotation to keep from falling. The time spent on the rod during each of three trials per day was measured and expressed in seconds. Testing was completed when the mouse fell off the rod (that is, from a height of 12 cm).
Intrathecal injections and drugs
The intrathecal injections were performed as described (44) . All intrathecally delivered drugs were injected in a 2-ml volume. Mifepristone (1 nmol in 2 ml) was purchased from Sigma and was dissolved in 10% ethanol in saline. Control animals received 2 ml of 10% ethanol in saline. SAFit2 was obtained from F. Hausch (Max Planck Institute) and used at a concentration of 2 mg/ml (4 mg in 2 ml), in 4% ethanol, 5% PEG400 (polyethylene glycol 400), 5% Tween 80 in 0.9% saline. Control animals received 2 ml of 4% ethanol, 5% PEG400, 5% Tween 80 in 0.9% saline.
Small interfering RNA
In vivo silencing of the protein FKBP51 was achieved with a mousespecific siRNA (Thermo Scientific; SMARTpool E-040262-00-0020). The siRNA was reconstituted in ribonuclease-free H 2 O to a final concentration of 0.5 or 2 mg/ml. Intrathecal injection of the siRNA solution (2 ml per mouse) was performed, as described above, for three consecutive days according to the experimental protocol. Control-treated animals received 2 ml of Accell Non-targeting Pool (D-001910-10-20) prepared in the same concentrations as the targeting siRNA. Intrathecally delivered siRNA reached the spinal cord ( fig. S7 ), and the siRNA treatment was optimized to one daily injection of 4 mg of siRNA on three consecutive days.
Blood sampling and corticosterone assay Blood was collected in the morning between 9:00 and 11:00 from mice tail vein. Before sampling, mice were placed in a warming cabinet (39°C for 10 to 15 min) to dilate the blood vessel. The levels of corticosterone were measured using an ELISA kit (ab108821, Abcam) following the manufacturer's protocol.
RNA preparation and RT-qPCR
For fresh tissue collection, animals were terminally anesthetized with CO 2 3 days after CFA or sham surgery. Total RNA was extracted using an acid phenol extraction method (TRIzol reagent, RNeasy mini-columns, QIAGEN), and complementary DNA was obtained as described (10) . Reactions were performed at least in triplicate, and the specificity of the products was determined by melting curve analysis. The ratio of the relative expression of target genes to b-actin was calculated by using the 2 DCt formula. Efficiencies of qPCRs were calculated for each gene using serial dilution.
DNA methylation analysis DNA extraction and bisulphite treatment: DNA was isolated from dorsal horn quadrants of rat spinal cord using DNeasy Blood and Tissue kit (QIAGEN). Bisulphite conversion of 100 ng of genomic DNA was achieved through the use of the EpiTect Bisulfite Kit (QIAGEN) according to the manufacturer's instructions. Details of PCR and pyrosequencing can be found in the Supplementary Materials.
Immunohistochemistry and Western blot
Immunohistochemistry and Western blot were performed as described (10) . For details, see the Supplementary Materials.
Data analysis
All statistical tests were performed in IBM SPSS Statistics 20. For the behavioral experiments, statistical analysis was performed on the data normalized by log transformation [von Frey data; as suggested by Mills et al. (45) ] or raw data, as presented in the figures. Behavioral data were also presented and analyzed without log transformation, and statistically significant effects for all groups were also observed with data presented as von Frey force in grams ( fig. S8 ). The significance of any differences in sensitivity was assessed using repeated-measures twoway or one-way ANOVA, as appropriate. In all cases, a significant effect of the main factor(s), or interactions between them, was taken as the criterion for progressing to post hoc analysis. Bonferroni analysis was the preferred post hoc analysis; however, if the general ANOVA was significant but no Bonferroni significance was observed, we also reported the results of the LSD post hoc analysis. In all cases, "time" was treated as a within-subjects factor, and "genotype" and "treatment" were treated as between-subject factors. For the RT-qPCR experiments, data were analyzed by univariate analysis for individual genes followed by the appropriate post hoc analysis (as above). Biological samples for the DNA methylation experiments (n = 6 in each group) and the measures of glucocorticoid levels (n = 4 in each group) were analyzed twice, and data of the technical replicates were examined by nested ANOVA. Data from all experiments are available in table S1.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/8/325/325ra19/DC1 Materials and Methods Fig. S1 . Global deletion of FKBP51 does not affect the expression of CGRP and IB4 in the superficial dorsal horn. Fig. S2 . Global deletion of FKBP51 does not affect CFA-induced cFos or pERK protein levels in the superficial dorsal horn. Fig. S3 . Global deletion of FKBP51 does not affect SNI-induced Iba1 expression in the superficial dorsal horn. Fig. S4 . Reduction of spinal FKBP51 expression with siRNA has no effect on basal mechanical threshold and locomotor activity. Fig. S5 . Global deletion of FKBP51 does not affect GR protein expression in naïve and injured wild-type and KO mice. Table S1 . Data from all experiments (Excel file).
